How it Works

Vyxeos (also known as CPX-351) is a chemotherapy drug that is used to treat acute myeloid leukemia (AML). It is a liposomal formulation of two chemotherapy drugs, cytarabine and daunorubicin, which are encased in small fat particles called liposomes.

Vyxeos works by interfering with the production of DNA and RNA, which are essential for the growth and division of cancer cells. It is specifically designed to release the chemotherapy drugs directly into the cancer cells, which can help to kill the cancer cells more effectively and minimize the side effects associated with chemotherapy.

How it’s Administered

• Vyxeos is usually given as an intravenous (IV) injection, which means that it is injected into a vein.

Who Should Take Vyxeos 

• It is indicated for adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), two types of AML having a poor prognosis. 

Who Shouldn’t Take Vyxeos

• Patients that have a severe allergy to vyxeos, daunorubicin, cytarabine, or any of its components.

• Pregnant women. It is important to inform your healthcare provider if you are pregnant, or planning to become pregnant before starting treatment, as it may cause harm to the fetus.

• Breastfeeding women should suspend breastfeeding if they start taking this medication. 

• It may not be recommended for use in patients with severe kidney or liver problems.

The Most Common Side Effects of Taking Vyxeos Include:

• Decreased blood cell counts: Your levels of platelets, white and red blood cells may temporarily drop. Which may cause, fatigue, weakness, shortness of breath, increased risk of infections, bleeding or bruising. 

• Nausea and vomiting, diarrhea, loss of appetite, mouth sores

• Hair loss (alopecia)

• Rash or redness of the skin

• Difficulty breathing, chest pain or tightness

Commonly Used in Acute Myeloid Leukemia With

• As standalone therapy.

TAKE A LOOK AT THE AVAILABLE CLINICAL TRIALS FOR AML

For more information click here

Date last updated: 12/22/22